Last reviewed · How we verify
NCT06962891: KidneySign
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
trial testing CKD progression biomarker in Chronic Kidney Disease(CKD) in 213 participants. Participants enrolled and being followed up; not accepting new ones.
1 March 2026
Quick facts
| Lead sponsor | Angel Argiles |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 213 |
| Start date | 2 May 2023 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 3 locations across Austria, France, Germany |
Drugs / interventions tested
- CKD progression biomarker
Conditions studied
- Chronic Kidney Disease(CKD) — all drugs for Chronic Kidney Disease(CKD) →
- Progression, Disease — all drugs for Progression, Disease →
Sponsor
Angel Argiles
Who can join
Adults 18 to 85, any sex, with Chronic Kidney Disease(CKD) or Progression, Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (CKD) progression, in CKD patients attending nephrology visits in 3 participating centres. The primary endpoint of CKD progression is defined as a relative change in eGFR observed at 1 year below -10%. The performance of the candidate biomarker will be compared to performances of UAE and KFRE equations. Participants will attend two study visits (baseline and 1-year), with clinical evaluation including kidney parameters (eGFR, urinary albumin excretion (UAE)) and collection of biological samples (plasma, serum, urine) for candidate proteomic biomarker evaluation. If planned in routine, patients will also have creatinine clearance estimation from 24-hour urine collection, kidney echography and kidney biopsy, sample biobanking and/or questionnaires and interviews on social and ethical aspects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06962891
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Disease(CKD)
Currently open trials in the same condition.
- NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
- NCT06906640 — Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) · NA · recruiting
- NCT06906627 — Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) · NA · recruiting
- NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
- NCT06940414 — Prevalence and Risk Factors of Hyperkalemia in Non-Dialysis Chronic Kidney Disease Patients in Community · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06962891 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Angel Argiles
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06962891.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing